Synthesis and structure based optimization of novel Akt inhibitors

被引：80

作者：

Lippa, Blaise ^{[1
]}

Pan, Gonghua ^{[1
]}

Corbett, Matthew ^{[1
]}

Li, Chao ^{[1
]}

Kauffman, Goss S. ^{[1
]}

Pandit, Jayvardhan ^{[1
]}

Robinson, Shaughnessy ^{[1
]}

Wei, Liuqing ^{[1
]}

Kozina, Ekaterina ^{[1
]}

Marr, Eric S. ^{[1
]}

Borzillo, Gary ^{[1
]}

Knauth, Elisabeth ^{[1
]}

Barbacci-Tobin, Elsa G. ^{[1
]}

Vincent, Patrick ^{[1
]}

Troutman, Merin ^{[1
]}

Baker, Deborah ^{[1
]}

Rajamohan, Francis ^{[1
]}

Kakar, Shefali ^{[1
]}

Clark, Tracey ^{[1
]}

Morris, Joel ^{[1
]}

机构：

[1] Pfizer Inc, PGRD Groton, Groton, CT 06340 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 11期

关键词：

Akt; pyrrolopyrimidine; spiroindoline; imidazopiperidine;

D O I：

10.1016/j.bmcl.2008.04.034

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Based on a high throughput screening hit, pyrrolopyrimidine inhibitors of the Akt kinase are explored. X-ray co-crystal structures of two lead series results in the understanding of key binding interactions, the design of new lead series, and enhanced potency. The syntheses of these series and their biological activities are described. Spiroindoline 13j is found to have an Akt1 kinase IC(50) of 2.4 +/- 0.6 nM, Akt cell potency of 50 +/- 19 nM, and provides 68% inhibition of tumor growth in a mouse xenograft model (50 mg/kg, qd, po). (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：3359 / 3363

页数：5

共 25 条

[1] Perturbations of the AKT signaling pathway in human cancer [J].

Altomare, DA ;

Testa, JR .

ONCOGENE, 2005, 24 (50) :7455-7464

[2]

BELLACOSA A, 1993, ONCOGENE, V8, P745

[3]

BORZILLO GV, 2005, DRUG DISCOV TODAY TH, V2, P331

[4] Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase a and mutants [J].

Breitenlechner, CB ;

Friebe, WG ;

Brunet, E ;

Guido, W ;

Graul, M ;

Thomas, U ;

Künkele, KP ;

Schäfer, W ;

Gassel, M ;

Bosseineyer, D ;

Huber, R ;

Engh, RA ;

Masjost, B .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (01) :163-170

[5] A transforming mutation in the pleckstrin homology domain of AKT1 in cancer [J].

Carpten, John D. ;

Faber, Andrew L. ;

Horn, Candice ;

Donoho, Gregory P. ;

Briggs, Stephen L. ;

Robbins, Christiane M. ;

Hostetter, Galen ;

Boguslawski, Sophie ;

Moses, Tracy Y. ;

Savage, Stephanie ;

Uhlik, Mark ;

Lin, Aimin ;

Du, Jian ;

Qian, Yue-Wei ;

Zeckner, Douglas J. ;

Tucker-Kellogg, Greg ;

Touchman, Jeffrey ;

Patel, Ketan ;

Mousses, Spyro ;

Bittner, Michael ;

Schevitz, Richard ;

Lai, Mei-Huei T. ;

Blanchard, Kerry L. ;

Thomas, James E. .

NATURE, 2007, 448 (7152) :439-U1

[6] Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design [J].

Donald, Alastair ;

McHardy, Tatiana ;

Rowlands, Martin G. ;

Hunter, Lisa-Jane K. ;

Davies, Thomas G. ;

Berdini, Valerio ;

Boyle, Robert G. ;

Aherne, G. Wynne ;

Garrett, Michelle D. ;

Collins, Ian .

JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (10) :2289-2292

[7]

FAYARD E, 2005, J CELL SCI, V24, P7455

[8] A STUDY OF ELECTROPHILIC SUBSTITUTION IN PYRROLO[2,3-D]PYRIMIDINE RING [J].

GERSTER, JF ;

HINSHAW, BC ;

ROBINS, RK ;

TOWNSEND, LB .

JOURNAL OF HETEROCYCLIC CHEMISTRY, 1969, 6 (02) :207-&

[9]

HABERMEHL GG, 1976, HETEROCYCLES, V5, P127

[10] Ligand efficiency: a useful metric for lead selection [J].

Hopkins, AL ;

Groom, CR ;

Alex, A .

DRUG DISCOVERY TODAY, 2004, 9 (10) :430-431

← 1 2 3 →